Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.
See Zacks' 3 Best Stocks to Play This Trend > Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. Intravenous andexanet alfa coagulation factor Xa (recombinant), inactivated-zhzo Andexxa is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors. Drug is still under investigation by the. Ondexxya (andexanet alfa) is a recombinant protein specifically designed to bind to FXa inhibitors and rapidly reverse their anticoagulant effect. By 2020, it's predicted to blast through the roof to $47 billion. Andexxa is the only FDA approved antidote to Eliquis and Xarelto, the bloodthinners whose combined sales exceeded 17bn in 2018 according to estimates. Last year, it generated $8 billion in global revenues. The stock has surged 35.4% in the past six months. Find medical information for RectiCare Advanced Cream on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures.
The company delivered positive earnings surprise in three of the trailing four quarters with the average beat being 17.04%. It is the first and only antidote for life-threatening or. You can see the complete list of today’s Zacks #1 Rank stocks here.īioSpecifics’ earnings estimates have been revised upward from $2.38 to $2. The FDA approval for Andexaa came Thursday, 19 months after the agency’s rejection of the breakthrough designated orphan drug. BioSpecifics Technologies Corp BSTC is another top-ranked stock from the same space, sporting a Zacks Rank #1 (Strong Buy). Portola currently carries a Zacks Rank #2 (Buy).
0 kommentar(er)
